CY1122631T1 - Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων - Google Patents

Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων

Info

Publication number
CY1122631T1
CY1122631T1 CY20201100131T CY201100131T CY1122631T1 CY 1122631 T1 CY1122631 T1 CY 1122631T1 CY 20201100131 T CY20201100131 T CY 20201100131T CY 201100131 T CY201100131 T CY 201100131T CY 1122631 T1 CY1122631 T1 CY 1122631T1
Authority
CY
Cyprus
Prior art keywords
grbar1
tgr5
fxr
prevention
treatment
Prior art date
Application number
CY20201100131T
Other languages
English (en)
Inventor
Angela ZAMPELLA
Stefano Fiorucci
Original Assignee
Bar Pharmaceuticals S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bar Pharmaceuticals S.R.L. filed Critical Bar Pharmaceuticals S.R.L.
Publication of CY1122631T1 publication Critical patent/CY1122631T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J11/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0094—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing nitrile radicals, including thiocyanide radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε ενώσεις που έχουν ικριώματα χολάνης, με τις εν λόγω ενώσεις για χρήση στη θεραπευτική αγωγή ή/και πρόληψη FΧR και μεσολαβούμενων από ΤGR5/GΡΒΑR1 ασθενειών.
CY20201100131T 2014-05-29 2020-02-12 Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων CY1122631T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITFI20140130 2014-05-29
PCT/EP2015/061802 WO2015181275A1 (en) 2014-05-29 2015-05-28 Cholane derivatives for use in the treatment and/or prevention of fxr and tgr5/gpbar1 mediated diseases

Publications (1)

Publication Number Publication Date
CY1122631T1 true CY1122631T1 (el) 2021-03-12

Family

ID=51454763

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100131T CY1122631T1 (el) 2014-05-29 2020-02-12 Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων

Country Status (24)

Country Link
US (2) US10407462B2 (el)
EP (2) EP3626725B1 (el)
JP (1) JP6820253B2 (el)
KR (1) KR102491556B1 (el)
CN (2) CN106661079B (el)
AU (1) AU2015265893B2 (el)
CA (1) CA2948585C (el)
CY (1) CY1122631T1 (el)
DK (2) DK3626725T3 (el)
EA (1) EA032820B1 (el)
ES (2) ES2938874T3 (el)
FI (1) FI3626725T3 (el)
HR (2) HRP20230170T1 (el)
HU (2) HUE061506T2 (el)
LT (2) LT3626725T (el)
MA (1) MA39881B1 (el)
MX (2) MX2020004024A (el)
PH (1) PH12016502327A1 (el)
PL (2) PL3626725T3 (el)
PT (2) PT3626725T (el)
RS (2) RS59910B1 (el)
SG (2) SG10201809362RA (el)
SI (2) SI3149019T1 (el)
WO (1) WO2015181275A1 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SI3149019T1 (sl) * 2014-05-29 2020-03-31 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in / ali preprečevanju FXR in TGR5 / GPBAR1 posredovanih bolezni
CN106459136B (zh) * 2014-09-28 2018-06-26 江苏盛迪医药有限公司 一种奥贝胆酸的制备方法
MX2017005935A (es) 2014-11-06 2018-01-11 Enanta Pharm Inc Análogos de ácido biliar como agonistas fxr/tgr5 y métodos de uso de los mismos.
CN111944006B (zh) * 2014-11-17 2021-12-17 正大天晴药业集团股份有限公司 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途
ES2759725T3 (es) 2014-11-19 2020-05-12 Nzp Uk Ltd Esteroides 6-alquil-7-hidroxi-4-en-3-ona como intermediarios para la producción de moduladores de FXR esteroideo
EA033445B1 (ru) 2014-11-19 2019-10-31 Nzp Uk Ltd 5-бета-6-алкил-7-гидрокси-3-оновые стероиды в качестве промежуточных соединений для получения стероидных модуляторов fxr
MX2017006565A (es) 2014-11-19 2018-01-26 Nzp Uk Ltd Esteroides 6.alfa.-alquil-3,7-diona como intermedios para la produccion de moduladores esteroides del receptor x farnesoide (fxr).
KR102527821B1 (ko) 2014-11-19 2023-05-02 엔제트피 유케이 리미티드 스테로이드 FXR 조절인자를 제조하기 위한 중간체로서의 6α-알킬-6,7-다이온 스테로이드
EP3223823A4 (en) 2014-11-26 2018-10-17 Enanta Pharmaceuticals, Inc. Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
US11578097B2 (en) 2014-11-26 2023-02-14 Enanta Pharmaceuticals, Inc. Tetrazole derivatives of bile acids as FXR/TGR5 agonists and methods of use thereof
US10208081B2 (en) 2014-11-26 2019-02-19 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
AU2016219266A1 (en) 2015-02-11 2017-08-10 Enanta Pharmaceuticals, Inc. Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
KR102681304B1 (ko) 2015-03-31 2024-07-03 이난타 파마슈티칼스, 인코포레이티드 Fxr/tgr5 작용제로서의 담즙산 유도체 및 이의 이용 방법
ES2873088T3 (es) 2015-06-19 2021-11-03 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos para su uso
JP2018528230A (ja) 2015-09-24 2018-09-27 インターセプト ファーマシューティカルズ， インコーポレイテッド 胆汁酸誘導体の調製のための方法および中間体
US10323061B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Heteroaryl containing bile acid analogs as FXR/TGR5 agonists and methods of use thereof
US10323060B2 (en) 2016-02-23 2019-06-18 Enanta Pharmaceuticals, Inc. Benzoic acid derivatives of bile acid as FXR/TGR5 agonists and methods of use thereof
US10364267B2 (en) 2016-02-23 2019-07-30 Enanta Pharmaceuticals, Inc. Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
EP3426348B1 (en) 2016-03-11 2021-05-05 Intercept Pharmaceuticals, Inc. 3-desoxy derivative and pharmaceutical compositions thereof
CN105859817A (zh) * 2016-05-09 2016-08-17 成都宇西医药技术有限公司 一种制备3α-羟基-6-乙烯基-7-酮基-5β-胆烷酸的方法
GB201608777D0 (en) 2016-05-18 2016-06-29 Dextra Lab Ltd Compounds
WO2017207648A1 (en) 2016-05-31 2017-12-07 Bionice, S.L.U Process and intermediates for the preparation of obeticholic acid and derivatives thereof
EP3464316A4 (en) * 2016-06-01 2020-02-19 Dr. Reddy's Laboratories Ltd. PROCESS FOR THE PREPARATION OF OBETICHOLIC ACID
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
ES2921432T3 (es) 2016-06-13 2022-08-25 Gilead Sciences Inc Derivados de azetidina como moduladores de FXR (NR1H4)
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
CA3045023A1 (en) 2016-11-29 2018-06-07 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonylurea bile acid derivatives
US10472386B2 (en) 2017-02-14 2019-11-12 Enanta Pharmaceuticals, Inc. Bile acid derivatives as FXR agonists and methods of use thereof
KR20220119520A (ko) 2017-03-28 2022-08-29 길리애드 사이언시즈, 인코포레이티드 간 질환을 치료하기 위한 치료 조합물
EP3606533B1 (en) * 2017-04-07 2023-11-15 Enanta Pharmaceuticals, Inc. Process for preparation of sulfonyl carbamate bile acid derivatives
CN109021056B (zh) * 2017-06-09 2021-03-09 博瑞生物医药（苏州）股份有限公司 法尼酯x受体激动剂
CN109021055B (zh) * 2017-06-09 2021-04-09 博瑞生物医药（苏州）股份有限公司 Fxr激动剂
CN109021054B (zh) * 2017-06-09 2021-04-09 博瑞生物医药（苏州）股份有限公司 一种fxr激动剂
US11059854B2 (en) * 2017-07-26 2021-07-13 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing steroid derivative FXR agonist
EP3705487B1 (en) * 2017-11-02 2022-10-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Method for preparing cholic acid compound
PT3911647T (pt) 2019-01-15 2024-03-04 Gilead Sciences Inc Composto de isoxazole como agonista de fxr e composições farmacêuticas que o contenham
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ， インコーポレイテッド Ｆｘｒアゴニストの固体形態
JP2022552655A (ja) 2019-10-07 2022-12-19 キャリーオペ，インク． Ｇｐｒ１１９アゴニスト
CN112824425B (zh) * 2019-11-21 2023-10-03 成都西岭源药业有限公司 一种6-位烯基取代胆酸化合物及其制备方法和应用
IT202000008515A1 (it) * 2020-04-21 2021-10-21 Bar Pharmaceuticals Soc A Responsabilita Limitata Metodo per la sintesi di un derivato del colano
CA3178994A1 (en) 2020-05-19 2021-11-25 Iyassu Sebhat Ampk activators
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
IT202200011705A1 (it) * 2022-06-01 2023-12-01 Prec Bio Therapeutics S R L Derivati del colesterolo e loro usi
WO2024006537A1 (en) * 2022-07-01 2024-01-04 Intercept Pharmaceuticals, Inc. Methods for ameliorating cognitive impairment using bile acid derivatives
IT202200018669A1 (it) 2022-09-13 2024-03-13 Bar Pharmaceuticals Soc A Responsabilita Limitata Combinazioni farmaceutiche comprendenti derivati del colano e loro usi
WO2024097247A1 (en) * 2022-10-31 2024-05-10 Intercept Pharmaceuticals, Inc. Uses of farnesoid x receptor agonists
WO2024195903A1 (ko) * 2023-03-21 2024-09-26 경희대학교 산학협력단 신규한 콜린산 유도체 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE433106T1 (de) * 1998-12-23 2009-06-15 Glaxo Group Ltd Bestimmungsmethode fur liganden der nuklearen rezeptoren
DE60205891T2 (de) * 2001-03-12 2006-06-22 Intercept Pharmaceuticals, Inc. Steroide als agonisten für fxr
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
PT2712617T (pt) * 2004-03-12 2017-02-13 Intercept Pharmaceuticals Inc Tratamento de fibrose usando ligandos fxr
ITMI20050912A1 (it) * 2005-05-19 2006-11-20 Erregierre Spa Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
WO2008002573A2 (en) * 2006-06-27 2008-01-03 Intercept Pharmaceuticals, Inc. Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated deseases or conditions
US8940719B2 (en) * 2006-07-03 2015-01-27 Academia Sinica Lithocholic acid analogues that inhibit sialyltransferase
FR2908310B1 (fr) * 2006-11-14 2009-07-10 Phytodia Produits agonistes de tgr5 et leurs applications
EP1947108A1 (en) * 2007-01-19 2008-07-23 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
CA2676417C (en) * 2007-01-19 2016-06-28 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
US8796249B2 (en) * 2008-07-30 2014-08-05 Intercept Pharmaceuticals, Inc. TGR5 modulators and methods of use thereof
ES2774368T3 (es) * 2008-11-19 2020-07-20 Intercept Pharmaceuticals Inc Moduladores de TGR5 y métodos de uso de los mismos
LT2698375T (lt) * 2008-11-19 2018-07-10 Intercept Pharmaceuticals, Inc. Tgr5 moduliatoriai ir jų panaudojimo būdas
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
US20130261317A1 (en) * 2010-09-27 2013-10-03 Kythera Biopharmaceuticals, Inc. Methods for preparing synthetic bile acids and compositions comprising the same
US20130034536A1 (en) 2011-08-04 2013-02-07 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Pancreatitis
US9238673B2 (en) * 2012-06-19 2016-01-19 Intercept Pharmaceuticals, Inc. Preparation and uses of obeticholic acid
EP2912013B1 (en) * 2012-10-26 2017-10-11 Intercept Pharmaceuticals, Inc. Process for preparing bile acid derivatives
US20140206657A1 (en) * 2013-01-18 2014-07-24 City Of Hope Bile acid analog tgr5 agonists
CN103143021A (zh) * 2013-03-21 2013-06-12 中国药科大学 PPARα-UGT通路抑制剂在治疗炎性肠疾病中的应用
PE20160665A1 (es) * 2013-05-14 2016-08-07 Intercept Pharmaceuticals Inc Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
CA2920017C (en) * 2013-08-01 2021-11-23 Frank J. Gonzalez Inhibitors of the farnesoid x receptor and uses in medicine
WO2015183794A1 (en) * 2014-05-27 2015-12-03 City Of Hope Tgr5 agonist complexes for treating diabetes and cancer
SI3149019T1 (sl) 2014-05-29 2020-03-31 Bar Pharmaceuticals S.R.L. Derivati holana za uporabo pri zdravljenju in / ali preprečevanju FXR in TGR5 / GPBAR1 posredovanih bolezni
US20170233431A1 (en) * 2016-02-17 2017-08-17 City Of Hope Bile acid derivatives and methods for synthesis and use

Also Published As

Publication number Publication date
MX2020004024A (es) 2021-12-10
ES2768718T3 (es) 2020-06-23
RS64050B1 (sr) 2023-04-28
FI3626725T3 (fi) 2023-03-16
EP3149019A1 (en) 2017-04-05
BR112016028085A2 (pt) 2017-08-22
CN106661079A (zh) 2017-05-10
SI3149019T1 (sl) 2020-03-31
WO2015181275A8 (en) 2016-02-18
AU2015265893A1 (en) 2016-12-08
JP6820253B2 (ja) 2021-01-27
EP3626725B1 (en) 2022-11-30
SG11201609403UA (en) 2016-12-29
US11117926B2 (en) 2021-09-14
MA39881B1 (fr) 2020-02-28
EP3626725A1 (en) 2020-03-25
JP2017516856A (ja) 2017-06-22
WO2015181275A1 (en) 2015-12-03
DK3149019T3 (da) 2020-02-17
HUE048351T2 (hu) 2020-07-28
HUE061506T2 (hu) 2023-07-28
US20190352328A1 (en) 2019-11-21
LT3626725T (lt) 2023-03-10
MX2016015724A (es) 2017-07-11
ES2938874T3 (es) 2023-04-17
US20170190731A1 (en) 2017-07-06
HRP20230170T1 (hr) 2023-03-31
PL3149019T3 (pl) 2020-07-27
CN110003301A (zh) 2019-07-12
EA032820B1 (ru) 2019-07-31
SI3626725T1 (sl) 2023-04-28
CA2948585A1 (en) 2015-12-03
CN106661079B (zh) 2019-03-01
AU2015265893B2 (en) 2020-11-12
RS59910B1 (sr) 2020-03-31
PT3626725T (pt) 2023-02-23
KR20170008767A (ko) 2017-01-24
SG10201809362RA (en) 2018-11-29
KR102491556B1 (ko) 2023-01-25
PT3149019T (pt) 2020-02-19
PL3626725T3 (pl) 2023-04-03
DK3626725T3 (da) 2023-02-27
CA2948585C (en) 2022-07-26
US10407462B2 (en) 2019-09-10
EP3149019B1 (en) 2019-12-04
HRP20200225T1 (hr) 2020-05-29
LT3149019T (lt) 2020-02-25
EA201692316A1 (ru) 2017-03-31
CN110003301B (zh) 2022-06-10
PH12016502327A1 (en) 2017-02-06

Similar Documents

Publication Publication Date Title
CY1122631T1 (el) Παραγωγα χολανης για χρηση στη θεραπευτικη αγωγη ή/και προληψη fxr και μεσολαβουμενων απο τgr5/gρβαr1 ασθενειων
CY1124663T1 (el) Αντιιικα παραγωγα ν4-υδροξυκυτιδινης
CY1125436T1 (el) Αναστολεις dna-pk
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1123603T1 (el) Αγωγη κακοηθειων β-κυτταρων μεσω συνδυασμου jak και ρι3κ αναστολεα
CY1121653T1 (el) C1-inh συνθεσεις και μεθοδοι για την προληψη και αγωγη διαταραχων συνδεομενων με ανεπαρκεια αναστολεα c1 εστερασης
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1124215T1 (el) Μκ2 αναστολεις και χρησεις αυτων
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
DOP2016000173A (es) Heteroarilos y usos de estos
MA53399A (fr) Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine
CY1123290T1 (el) Ενωσεις και μεθοδοι χρησης
EA201790575A1 (ru) Триазолопиразиноны в качестве ингибиторов pde1
CY1123920T1 (el) Αντιγριπικο πολυκυκλικο παραγωγο πυριδονης και προφαρμακο αυτου
BR112018011709A2 (pt) inibidores bicíclicos de pad4
CY1124406T1 (el) Αζασετρονη για χρηση στη θεραπεια της απωλειας ακοης
DK3865484T3 (da) Pde9-hæmmer med imidazopyrazinon-rygrad til behandling af perifere sygdomme
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
EA201790312A1 (ru) Комбинации лекарственных средств для лечения множественной миеломы
DK3097085T3 (da) Benzoxazinonderivater til behandling af hudsygdomme
DK3236983T3 (da) Hidtil ukendt pi3k-gamma-inhibitorpeptid til behandling af sygdomme i åndedrætssystemet
DK3153511T3 (da) 2-acylaminothiazolderivat til anvendelse i forebyggelsen eller behandlingen af blære- og urinvejssygdomme
MA43052A (fr) Inhibiteurs de la kallicréine plasmatique humaine